Benign Conditions

Data from a recent multicenter study provide new evidence that the beta-3 adrenoceptor agonist mirabegron (Myrbetriq) appears to be a viable alternative in patients with overactive bladder who are poor responders to antimuscarinic agents or intolerant of their adverse events.

THVD-201 (Tolenix), a novel formulation combining tolterodine and pilocarpine, was found safe, well tolerated, and effective against overactive bladder (OAB) in a recent study.

The algorithm for urologists’ approach to male voiding symptoms is evolving, according to Steven A. Kaplan, MD, of Weill Cornell Medical College, New York. This will be evident in presentations on BPH and lower urinary tract symptoms at the AUA annual meeting.

As in adult urology, minimally invasive approaches continue to grow in pediatric urology, which is reflected in the research being presented at this year’s AUA annual meeting.

Men with BPH may obtain symptomatic relief with minimally invasive prostatic artery embolization (PAE), according to results from a small, prospective study.

Shared medical appointments for kidney stone patients are more beneficial than individual appointments, according to researchers from the University of Wisconsin School of Medicine and Public Health, Madison.

For women with uncomplicated, stress-predominant incontinence, urodynamic testing adds considerable expense without improving surgical outcomes, a recent trial shows.

Preoperative urodynamic testing in women undergoing surgery for uncomplicated, stress-predominant urinary incontinence commonly results in a change in clinical diagnosis.

The FDA recently approved oxybutynin transdermal (Oxytrol for Women) over-the-counter treatment for overactive bladder in women ages 18 years and older.

Urologists discuss the treatments that have most affected their practices.

Exposure to a desert environment increases lithogenic risk, but the effect is the result of unanticipated changes in excretion of lithogenic material, according to a recent study.

Intradetrusor injections of onabotulinumtoxinA (Botox) do not significantly reduce urinary frequency in patients with refractory overactive bladder secondary to BPH, results from a two-institution, placebo-controlled study indicate.